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samples, and with a high prevalence of bronchiectasis–the latter
proving to be a major predictor of CBI. These factors may limit the
generalizability of the results and call for them to be validated.
Lastly, the definition of CBI was not based on a single baseline
assessment but on repeated sampling over time, which complicates
its clinical utility as a risk prediction tool and may have
confounded the observed relationship between CBI and
pneumonia.
The results of this study are biologically plausible and
logically appealing. The presence of low blood eosinophil counts
and/or CBI appear to be risk factors that increase pneumonia risk
and, therefore, influence the benefit–risk calculation for the use
of ICS in COPD. That said, large-scale, routine, and repeated
sputum collection and analysis poses logistic and implementation
challenges, particularly in primary care. Unless this practical hurdle
is overcome, it seems likely that decisions about ICS use will
remain part science, part art. n
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Airway Occlusion Pressure Revisited
The use of airway occlusion pressure (P0.1) as a measure of respiratory
drive was introduced by Whitelaw and colleagues 45 years ago based on
two basic assumptions (1). First, in the absence of flow or volume
change during the occlusion, pressure generated by the inspiratory
muscles is transmitted directly (1:1 ratio) to the external airway. Second,
if the occlusion is brief (i.e., 0.1 s), there is no time for behavioral
responses to influence the pressure output of the inspiratory muscles.
Hence, the change in airway pressure during a constant brief time
reflects the rate of rise of inspiratory muscle pressure at the beginning of
spontaneous inspiration, which has been shown to correlate well with
the rate of rise of inspiratory muscle activity, at least in normal subjects.
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Although the second tenet still holds true, several factors were
subsequently identified that can alter the relation between P0.1
and inspiratory muscle pressure or electrical diaphragm muscle output
in the absence of volume changes or behavioral responses. As noted by
Whitelaw and Derenne in 1993, these factors include the presence of
dynamic hyperinflation, expiratory muscle activity, chest wall
distortion, respiratory muscle weakness, neuromuscular junction
blockade, and the shape of the inspiratory pressure waveform (2). All of
these modifiers apply to critically ill patients. In addition, the method
used to measure P0.1 in such patients is of critical importance
depending on whether a true occlusion is implemented, whether
measurements are made close to the patient or remotely in the
ventilator, what type of triggering is used, and other technical factors.
Almost certainly, because of the numerous variables that modify the
relation between P0.1 and inspiratory muscle pressure output or drive,
the results of P0.1 in weaning assessments, even when measured
properly with specialized equipment, have been variable and generally
not impressive. There is, however, evidence that an excessively high
or excessively low respiratory drive in patients is an important
risk factor for continued ventilator dependence (3, 4). Identifying such
patients would be of clinical value because this might spare them from
being subjected to unsuccessful weaning trials and point to the
abnormality that needs to be addressed.
The use of specialized equipment to measure P0.1 in the ICU
is a major deterrent to such studies because the setup, proper
application of occlusion, and assessment of the quality of the
results require considerable expertise. Several commercially
available ventilators measure P0.1 and display the results on
the ventilator screen. The methods used by these ventilators
vary but do not include the desirable application of occlusion
near the patient’s airway, and some ventilators do not even apply
a true occlusion. An important practical question, therefore,
is whether the ventilator-generated P0.1 is an adequate surrogate
for the more complex and demanding use of specialized equipment.
In a study presented in this issue of the Journal, Telias
and colleagues (pp. 1086–1098) compared P0.1 estimated by different
commercial ventilators (P0.1vent) with values obtained in the proper
way (P0.1ref) in critically ill patients and in a bench test using a
simulator (5). In addition, they determined the relation between P0.1
and the pressure–time product of the inspiratory muscles. Not
surprisingly, there were good correlations between P0.1 and pressure
output in individual patients, consistent with the fact that airway
pressure is directly related to respiratory muscle output during
occluded breaths. Also, as expected from the various known modifiers
of the relationship between P0.1 and inspiratory muscle pressure,
there was much scatter in this relationship among patients. There are
several important novel findings from this study. First, P0.1 measured
by ventilators that apply a true end-expiratory occlusion accurately
reflects P0.1ref in bench testing, whereas ventilators that do not apply
occlusion are inaccurate. Second, on average, P0.1 measured by the
more accurate ventilators in patients has little systematic error
(minimal bias), and therefore these average values can be used to
evaluate the impact of P0.1 on outcomes in group comparisons. Third,
having defined a high respiratory output as P0.1.4.0 cm H2O and a
low output as,1.1 cm H2O measured by P0.1ref, and notwithstanding
the large differences between P0.1vent and P0.1ref in individual patients,
P0.1vent could identify patients above and below these thresholds with
reasonable accuracy. A limitation exists in that although the thresholds
of P0.1ref have been validated, those of P0.1vent have not.
These results are encouraging in that they suggest that P0.1
displayed in select ventilators can be used to identify patients with
abnormally high and low values. Some caveats remain, however. First,
as the authors acknowledge, the thresholds used to set limits on high
risk are derived from retrospective analyses of patients with weaning
failure. It is not clear whether respiratory muscle output in these
patients was the only or main reason for weaning failure. Second, the
thresholds selected here apply to only a small fraction of the patients
studied; in most patients, P0.1 was between the high and low
thresholds, and in such patients the P0.1 results would be equivocal.
Knowledge in physiology in the interpretation of P0.1 is
indispensable. In the extremes, as mentioned above, variables that
modify P0.1 measurements may create conflicting results regarding the
relationship between P0.1 (as an estimate of respiratory drive) and
inspiratorymuscle pressure output. In the presence ofmuscle weakness,
high chest wall elastance, dynamic hyperinflation, or chest
wall–abdominal paradox, a high respiratory drive associated with
respiratory distress may yield low inspiratory muscle effort and P0.1
(6). Conversely, a low respiratory drive is not inevitably associated
with low inspiratory muscle effort and low P0.1. For example,
expiratory muscle recruitment in response to external positive end-
expiratory pressure may be associated with high P0.1 despite a weak
inspiratory effort (2). Important questions remain: 1) what is the
threshold of inspiratory muscle effort–induced injury, and 2) does
monitoring of P0.1 and inspiratory muscle efforts in critically ill
patients receiving mechanical ventilation alter clinical outcomes?
Future prospective studies will need to address these questions. n
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